For laboratory research use only. Not for human or animal consumption.
BioIntegrityPeptide Research

Growth Factors

Tesamorelin / Ipamorelin

GH Blend

Tesamorelin and Ipamorelin blend

Research context

This preparation combines tesamorelin, a 44-residue GHRH receptor analogue, with ipamorelin, a selective growth hormone secretagogue receptor (GHS-R1a) agonist. The two act at distinct receptors, and each is characterised independently in the published literature; the blend itself has not been separately characterised.

Common assays: Component identity by LC-MS · Purity per component · Pituitary secretion assays

Specification

DesignationGH Blend
Full nameTesamorelin and Ipamorelin blend
ComponentsTesamorelin · Ipamorelin
Formats10 mL Vial
SolubilityBacteriostatic water, sterile water
StorageLyophilised: −20 °C. Reconstituted: 2–8 °C.

Published literature

Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.

  1. Raun K, Hansen BS, Johansen NL, et al.Ipamorelin, the first selective growth hormone secretagogueEuropean Journal of Endocrinology · 1998 Find on PubMed ↗

Common questions

How does this blend differ from CJC-1295 / Ipamorelin?

The GHRH-receptor component is tesamorelin, the full 44-residue sequence with an N-terminal acyl group, rather than CJC-1295, the 29-residue fragment with internal substitutions. The secretagogue component is the same.

How is a two-component blend verified?

Each component is identified and quantified separately by LC-MS and RP-HPLC, with results reported per component on the certificate.

Components, blends and pathway

Related compounds